Protein A here to stay according to GE Healthcare

Protein A here to stay according to GE Healthcare

Protein A will keep its key role in therapeutic mAb production but next generation biotherapeutics will see Protein L become increasingly import says GE Healthcare.

Last week experts told BioPharma-Reporter.com that, despite its $12,000 price tag and efforts to develop alternatives, Protein A will continue to be favoured by the monoclonal antibody (mAb) manufacturing sector.

One, Jonathan RF Robinson from the UK National Biologics Manufacturing Centre, told us that continued demand for Protein A will be good news for GE Healthcare which, in collaboration with partner Repligen, is the major Protein A supplier to the biopharmaceutical industry.

We put this to GE, which told us that: “Protein A-based affinity chromatography technology is currently the most robust and economic approach available for the commercial purification of monoclonal antibodies.

The firm also suggested that while efforts to develop alternatives to are ongoing – expanded bed adsorption, crystallization and precipitation among others – for the time being Protein A is likely to continue to be the go-to mAb capture technology.

“At the moment, in terms of yield, capacity, ease-of-scale up, ease-of-operation and ease-of-process development, Protein A offers significant advantages, leading to overall better process economy and shorter development times for new molecules.

GE also said that it is investing to improve the efficacy of Protein A-based resins, with the current focus being increasing their binding capacity and re-usability citing MabSelect SuRe LX as an example.

The enhanced capacity and stability of MabSelect SuRe LX helps improve process economy and product quality, and allows cleaning to be performed with cost-effective reagents such as sodium hydroxide thus eliminating the need for expensive and hazardous cleaning agents such as Gua-HCl.”

Protein L resins   

Another area of investment for GE is Protein L, which is a molecule found on the surface of the bacterial species Peptostreptococcus magnus that like Protein A and G also binds immunoglobulins.

However, unlike Proteins A or G which bind antibody Fc regions, Protein L interacts with immunoglobulin light chains which makes them useful for producers of fragment-based biopharmaceutical products according to GE.

“We are investing in the development of newer affinity resins for the purification of a next-generation of biotherapeutics such as antibody fragments – for example affinity resins based on Protein L.”  

Related News

Repligen: New CFO 'suited to growth path,' hints at acquisitions

Repligen: New CFO 'suited to growth path,' hints at acquisitions

Xcellerex site in Marlborough, Massachusetts, US

GE Healthcare: plans to move New Jersey ops to new Massachusetts HQ

Vendors' role in single-use plant design could cut costs, says M+W

Vendors' role in single-use plant design could cut costs, says M+W

Repligen expects higher tech revenues in 2015

Repligen finishes plant expansion and forecasts higher tech revenues in 2015

Green Cross constructing $255m Canadian immunoglobulin, albumin plant

Green Cross constructing $255m Canadian immunoglobulin and albumin plant

Protein A OK! Image: iStock/oanav

Repligen extends Protein A ligand supply deal with GE Healthcare

Purolite takes aim at GE's Protein A dominance with plant expansion

Purolite targets GE's Protein A resin dominance with plant expansion

New Welsh plant will give biomanufacturers a choice of suppliers for agarose resins and cut Protein A prices, says Purolite. Image: iStock/JohnnyLye

War of the agaroses? Purolite says 100,000L plant will cut cost of Protein A

iStock/Jag_cz

Merck opens €55m Irish plants supporting downstream consumables business

GE Healthcare shows Biopharma-reporter.com how it uses Microsoft's Xbox Kinect tech at trade events

Virtual Sterility? GE uses Xbox tech to showcase products

iStock/rep0rter

Ajinomoto Althea gets US patent for fast, industrial-scale antibody crystallization method

Graphic image from the new Protein A production facility in Wales, UK. c/o Purolite

Streamlined Protein A production will lower costs for mAb makers, Purolite

Image: iStock/sumos

Customisable chromatography resin maker Avitide boosted by Series D funding

Image: iStock/Stadtratte

German affinity chromatography tech firm changes hands, changes name

Crescendo raises £17m for Ab fragments made using novel tech

Crescendo raises £17m for Ab fragment drugs made using novel tech

Bioclon facility - which makes Arizona bark scorpion antivenom - hit with FDA warning

US FDA stings scorpion anti-venom biomanufacturer with Warning Letter

More investment in ADCs - 'warhead' cytotoxic small molecule linked to cancer-targeting mAb

MedImmune looks to 'next generation biologics' with $200m ADC investment

Talking ADCs with SAFC, Piramal and Catalent at CPhI Frankfurt

'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

Related Products

See more related products